257 related articles for article (PubMed ID: 37892181)
1. Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation.
Krauze AV; Zhao Y; Li MC; Shih J; Jiang W; Tasci E; Cooley Zgela T; Sproull M; Mackey M; Shankavaram U; Tofilon P; Camphausen K
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892181
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma survival is associated with distinct proteomic alteration signatures post chemoirradiation in a large-scale proteomic panel.
Krauze AV; Sierk M; Nguyen T; Chen Q; Yan C; Hu Y; Jiang W; Tasci E; Zgela TC; Sproull M; Mackey M; Shankavaram U; Meerzaman D; Camphausen K
Front Oncol; 2023; 13():1127645. PubMed ID: 37637066
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Watanabe S; Kuwabara Y; Suehiro S; Yamashita D; Tanaka M; Tanaka A; Ohue S; Araki H
Eur J Clin Pharmacol; 2017 Mar; 73(3):357-363. PubMed ID: 27889835
[TBL] [Abstract][Full Text] [Related]
5. The addition of Valproic acid to concurrent radiation therapy and temozolomide improves patient outcome: a Correlative analysis of RTOG 0525, SEER and a Phase II NCI trial.
Krauze AV; Megan M; Theresa CZ; Peter M; Shih JH; Tofilon PJ; Rowe L; Gilbert M; Camphausen K
Cancer Stud Ther; 2020 Mar; 5(1):. PubMed ID: 34621499
[TBL] [Abstract][Full Text] [Related]
6. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Happold C; Gorlia T; Chinot O; Gilbert MR; Nabors LB; Wick W; Pugh SL; Hegi M; Cloughesy T; Roth P; Reardon DA; Perry JR; Mehta MP; Stupp R; Weller M
J Clin Oncol; 2016 Mar; 34(7):731-9. PubMed ID: 26786929
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
Barker CA; Bishop AJ; Chang M; Beal K; Chan TA
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):504-9. PubMed ID: 23523186
[TBL] [Abstract][Full Text] [Related]
9. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
Chen JC; Lee IN; Huang C; Wu YP; Chung CY; Lee MH; Lin MH; Yang JT
BMC Cancer; 2019 Aug; 19(1):756. PubMed ID: 31370819
[TBL] [Abstract][Full Text] [Related]
11. Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.
Kuo YJ; Yang YH; Lee IY; Chen PC; Yang JT; Wang TC; Lin MH; Yang WH; Cheng CY; Chen KT; Huang WC; Lee MH
Medicine (Baltimore); 2020 Jul; 99(28):e21147. PubMed ID: 32664146
[TBL] [Abstract][Full Text] [Related]
12. Rapid valproic acid-induced modulation of the traumatic proteome in a porcine model of traumatic brain injury and hemorrhagic shock.
Weykamp M; Nikolian VC; Dennahy IS; Higgins GA; Georgoff PE; Remmer H; Ghandour MH; Alam HB
J Surg Res; 2018 Aug; 228():84-92. PubMed ID: 29907235
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
14. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
15. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
16. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Weller M; Gorlia T; Cairncross JG; van den Bent MJ; Mason W; Belanger K; Brandes AA; Bogdahn U; Macdonald DR; Forsyth P; Rossetti AO; Lacombe D; Mirimanoff RO; Vecht CJ; Stupp R
Neurology; 2011 Sep; 77(12):1156-64. PubMed ID: 21880994
[TBL] [Abstract][Full Text] [Related]
17. Molecular dissection of the valproic acid effects on glioma cells.
Hoja S; Schulze M; Rehli M; Proescholdt M; Herold-Mende C; Hau P; Riemenschneider MJ
Oncotarget; 2016 Sep; 7(39):62989-63002. PubMed ID: 27556305
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
Riva G; Butta V; Cilibrasi C; Baronchelli S; Redaelli S; Dalprà L; Lavitrano M; Bentivegna A
Oncol Rep; 2016 May; 35(5):2811-24. PubMed ID: 26986767
[TBL] [Abstract][Full Text] [Related]
19. Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.
McTyre E; Lucas JT; Helis C; Farris M; Soike M; Mott R; Laxton AW; Tatter SB; Lesser GJ; Strowd RE; Lo HW; Debinski W; Chan MD
Am J Clin Oncol; 2018 Aug; 41(8):813-819. PubMed ID: 28301347
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
